Pacer Advisors
VYGR icon

Pacer Advisors’s Voyager Therapeutics VYGR Stock Holding History

Pacer Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-508
Closed -$4.02K – 2710
2024
Q2 		$4.02K Sell
508
-46
-8% -$386 ﹤0.01% 3653
2024
Q1 		$5.16K Buy
+554
New +$4.68K ﹤0.01% 3592
2020
Q4 		– Sell
-1,540
Closed -$16K – 1541
2020
Q3 		$16K Buy
+1,540
New +$18.1K ﹤0.01% 1363
2018
Q4 		– Sell
-3,272
Closed -$62K – 1040
2018
Q3 		$62K Buy
+3,272
New +$62.8K ﹤0.01% 1131

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pacer Advisors's VYGR Position: Q3 2024 in Review

Pacer Advisors sold out of Voyager Therapeutics (VYGR) in Q3 2024, closing a stake of 508 shares — an estimated $4.02K sold.

Pacer Advisors first reported a position in VYGR in Q3 2018 and held it in 4 quarters. The position peaked at $62K in Q3 2018. 128 funds tracked by Wall St. Rank hold VYGR as of Q3 2024.

  • Pacer Advisors reported no remaining Voyager Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 508 Voyager Therapeutics shares in Q3 2024, an estimated $4.02K.
  • Pacer Advisors first reported a position in Voyager Therapeutics in Q3 2018 and held it in 4 quarters.
  • Pacer Advisors's Voyager Therapeutics position peaked at $62K in Q3 2018.
  • 128 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.